[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1165955A1 - -二甲基苯基硫基 苯基 哌嗪的提純 - Google Patents

-二甲基苯基硫基 苯基 哌嗪的提純

Info

Publication number
HK1165955A1
HK1165955A1 HK12106536.4A HK12106536A HK1165955A1 HK 1165955 A1 HK1165955 A1 HK 1165955A1 HK 12106536 A HK12106536 A HK 12106536A HK 1165955 A1 HK1165955 A1 HK 1165955A1
Authority
HK
Hong Kong
Prior art keywords
dimethylphenylsulfanyl
piperazine
purification
phenyl
Prior art date
Application number
HK12106536.4A
Other languages
English (en)
Inventor
Henrik Vigan Nicolajsen
De Diego Heidi Lopez
Michael Harold Rock
Original Assignee
．隆德貝克有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ．隆德貝克有限公司 filed Critical ．隆德貝克有限公司
Publication of HK1165955A1 publication Critical patent/HK1165955A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12106536.4A 2009-02-17 2012-07-04 -二甲基苯基硫基 苯基 哌嗪的提純 HK1165955A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900223 2009-02-17
PCT/DK2010/050039 WO2010094285A1 (en) 2009-02-17 2010-02-16 Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
HK1165955A1 true HK1165955A1 (zh) 2012-10-12

Family

ID=42101395

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106536.4A HK1165955A1 (zh) 2009-02-17 2012-07-04 -二甲基苯基硫基 苯基 哌嗪的提純

Country Status (28)

Country Link
US (1) US8598348B2 (zh)
EP (1) EP2398785B1 (zh)
JP (1) JP5738774B2 (zh)
KR (1) KR101639833B1 (zh)
CN (1) CN102317272B (zh)
AR (1) AR075436A1 (zh)
AU (1) AU2010214956B2 (zh)
BR (1) BRPI1006975B1 (zh)
CA (1) CA2751498C (zh)
CL (1) CL2011001992A1 (zh)
CO (1) CO6400224A2 (zh)
DK (1) DK2398785T3 (zh)
EA (1) EA020473B1 (zh)
ES (1) ES2441079T3 (zh)
HK (1) HK1165955A1 (zh)
HR (1) HRP20131236T1 (zh)
IL (1) IL214178A (zh)
MX (1) MX2011008661A (zh)
NZ (1) NZ594658A (zh)
PL (1) PL2398785T3 (zh)
PT (1) PT2398785E (zh)
RS (1) RS53074B (zh)
SG (1) SG173735A1 (zh)
SI (1) SI2398785T1 (zh)
SM (1) SMT201400010B (zh)
TW (1) TW201033181A (zh)
WO (1) WO2010094285A1 (zh)
ZA (1) ZA201105992B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133144B2 (en) 2012-01-03 2015-09-15 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
WO2014044721A1 (en) 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
KR102171152B1 (ko) 2012-12-13 2020-10-29 하. 룬드벡 아크티에셀스카브 보르티옥세틴 및 도네페질을 포함하는 조성물
SG11201506651SA (en) * 2013-02-22 2015-09-29 Lundbeck & Co As H Vortioxetine manufacturing process
WO2015035802A1 (zh) * 2013-09-12 2015-03-19 杭州普晒医药科技有限公司 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN103788020B (zh) * 2014-01-22 2015-11-04 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
CN105669594A (zh) * 2014-11-19 2016-06-15 康普药业股份有限公司 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法
CN105801517A (zh) * 2014-12-30 2016-07-27 上海奥博生物医药技术有限公司 一种沃替西汀氢溴酸盐新晶型及其制备方法
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016151328A1 (en) 2015-03-26 2016-09-29 Cipla Limited Method for making serotonin reuptake inhibitors
CN105367515B (zh) * 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
CN105439980B (zh) * 2015-05-08 2017-10-24 北京北陆药业股份有限公司 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法
CN106316985B (zh) * 2015-06-18 2021-11-09 郑州深蓝海生物医药科技有限公司 一种β型高效氢溴酸沃替西汀转晶方法
WO2017125504A1 (en) * 2016-01-20 2017-07-27 Amneal Pharmaceuticals Company Gmbh Polymorphic forms of vortioxetine hydrobromide tert-butanolate
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3615518B1 (en) * 2017-04-25 2021-12-15 H. Lundbeck A/S Process for the manufacture of vortioxetine hbr alpha-form
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
CN112125868B (zh) * 2020-09-25 2021-08-03 中山万远新药研发有限公司 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852974A (en) 1958-04-17 1960-11-02 Parke Davis & Co Ethers and means for producing the same
FR2186237B1 (zh) 1972-05-03 1975-10-31 Synthelabo
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EA015287B1 (ru) * 2006-06-16 2011-06-30 Х. Лундбекк А/С 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нти 5-нтдля лечения когнитивного нарушения
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

Also Published As

Publication number Publication date
PL2398785T3 (pl) 2014-07-31
HRP20131236T1 (hr) 2014-02-14
US8598348B2 (en) 2013-12-03
EA201171065A1 (ru) 2012-02-28
MX2011008661A (es) 2011-09-06
JP2012517961A (ja) 2012-08-09
AU2010214956B2 (en) 2012-08-23
CA2751498C (en) 2017-09-12
WO2010094285A1 (en) 2010-08-26
KR101639833B1 (ko) 2016-07-14
SI2398785T1 (sl) 2014-01-31
TW201033181A (en) 2010-09-16
KR20110126625A (ko) 2011-11-23
SG173735A1 (en) 2011-09-29
ES2441079T3 (es) 2014-01-31
NZ594658A (en) 2013-02-22
CL2011001992A1 (es) 2012-04-09
CO6400224A2 (es) 2012-03-15
AR075436A1 (es) 2011-03-30
ZA201105992B (en) 2012-10-31
US20120004409A1 (en) 2012-01-05
PT2398785E (pt) 2013-12-26
RS53074B (en) 2014-04-30
EP2398785A1 (en) 2011-12-28
CN102317272A (zh) 2012-01-11
IL214178A0 (en) 2011-08-31
CA2751498A1 (en) 2010-08-26
EP2398785B1 (en) 2013-11-27
EA020473B1 (ru) 2014-11-28
BRPI1006975A2 (pt) 2020-08-18
SMT201400010B (it) 2014-03-07
JP5738774B2 (ja) 2015-06-24
AU2010214956A1 (en) 2011-09-22
CN102317272B (zh) 2014-11-12
IL214178A (en) 2014-09-30
DK2398785T3 (da) 2013-12-16
BRPI1006975B1 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
HK1165955A1 (zh) -二甲基苯基硫基 苯基 哌嗪的提純
ZA201107731B (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
HRP20130819T1 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
ZA200907511B (en) Novel piperazine salts as D3/D2 antagonists
IL202666A0 (en) Substituted piperazines
ZA201201653B (en) Novel azaheterocyclic compounds
IL244059A0 (en) Phenoxymethyl heterocyclic compounds
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
GB0919817D0 (en) Heterocyclic compounds
GB0919816D0 (en) Heterocyclic compounds